This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Chronic lymphocytic leukemia (CLL)

Receptor tyrosine kinase-like orphan receptor 1 (ROR1)

Mouse studies suggest inhibiting ROR1 could help treat CLL. In transgenic mice expressing human ROR1 and T cell leukemia/lymphoma 1A (TCL1A) in B cells, CLL-like disease developed earlier than that in transgenic mice expressing either human gene alone. In ROR1 transgenic mice engrafted with leukemia cells expressing ROR1 alone or in combination with TCL1A, an antibody targeting human ROR1 decreased leukemic cell engraftment compared with IgG control. Ongoing studies include developing a humanized antibody targeting ROR1.
Kancera AB has a ROR1 inhibitor in discovery to treat CLL.

SciBX 7(4); doi:10.1038/scibx.2014.115
Published online Jan. 30, 2014

Patent application filed; available for licensing

Widhopf II, G.F. et al. Proc. Natl. Acad. Sci. USA; published online
Dec. 30, 2013;
doi:10.1073/pnas.1308374111
Contact: Thomas J. Kipps, University of California, San Diego, La Jolla, Calif.
e-mail:

tkipps@ucsd.edu